Twist Bioscience (NASDAQ:TWST – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11, MarketWatch Earnings reports. Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. The business had revenue of $66.95 million for the quarter, compared to analysts’ expectations of $63.35 million. During the same quarter in the previous year, the firm posted ($0.91) earnings per share. The company’s revenue was up 16.8% compared to the same quarter last year.
Twist Bioscience Trading Up 25.9 %
NASDAQ:TWST opened at $24.01 on Friday. The firm has a market capitalization of $1.38 billion, a PE ratio of -6.49 and a beta of 1.32. The stock has a 50 day moving average of $18.69 and a 200-day moving average of $19.07. Twist Bioscience has a 52 week low of $11.46 and a 52 week high of $31.51.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors lifted its stake in Twist Bioscience by 101.3% during the second quarter. Captrust Financial Advisors now owns 759 shares of the company’s stock valued at $27,000 after purchasing an additional 382 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Twist Bioscience by 155.6% during the first quarter. Canada Pension Plan Investment Board now owns 1,066 shares of the company’s stock valued at $52,000 after purchasing an additional 649 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of Twist Bioscience by 73.4% in the 1st quarter. Lazard Asset Management LLC now owns 1,597 shares of the company’s stock valued at $78,000 after acquiring an additional 676 shares in the last quarter. US Bancorp DE lifted its position in shares of Twist Bioscience by 257.1% in the 2nd quarter. US Bancorp DE now owns 2,050 shares of the company’s stock valued at $42,000 after acquiring an additional 1,476 shares in the last quarter. Finally, Amundi lifted its position in shares of Twist Bioscience by 30.5% in the 4th quarter. Amundi now owns 3,550 shares of the company’s stock valued at $95,000 after acquiring an additional 830 shares in the last quarter.
Analysts Set New Price Targets
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- Five stocks we like better than Twist Bioscience
- Retail Stocks Investing, Explained
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Best Restaurant Stocks to Invest in Now
- MarketBeat Week in Review – 11/13 – 11/17
- How to Start Investing in Penny Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.